Bionano Genomics, Inc. - BNGO STOCK NEWS

Bionano Genomics (Nasdaq: BNGO) has initiated a pilot program for its Saphyr system at the University Health Network's Laboratory Medicine Program in Toronto, Canada's largest hospital diagnostic lab. This program aims to enhance cancer diagnostics by employing optical genome mapping (OGM) to improve the detection of chromosomal abnormalities and reduce costs. With UHN performing 25 million tests annually, this collaboration represents a significant step forward in streamlining cytogenomic analysis and potentially transforming cancer diagnosis.

Bionano Genomics (Nasdaq: BNGO) announced the availability of presentation recordings from its recent Next-Generation Cytogenomics Symposium, held from January 11 to 15, where over 15,500 registrations were recorded. The event, featuring 33 presentations by Saphyr users, focused on optical genome mapping applications, including studies on genetic diseases and COVID-19. CEO Erik Holmlin highlighted the symposium's role in enhancing awareness of the Saphyr system, which aims to improve diagnostics and therapeutic targets. The recordings are accessible on Bionano's website and YouTube page.

Bionano Genomics (BNGO) announced a presentation by Dr. Gordana Raca from Children’s Hospital Los Angeles demonstrating the efficacy of optical genome mapping (OGM) using Saphyr for analyzing pediatric leukemias. OGM detected crucial structural variants (SVs) that standard methods—including NGS—missed, potentially impacting patient care. This method identified gene fusions and a novel Acute Lymphoblastic Leukemia subtype, showcasing OGM's advantages in precision and sensitivity over traditional techniques. CEO Erik Holmlin emphasized that Saphyr could transform cytogenomic testing in pediatric cancer.

Bionano Genomics (Nasdaq: BNGO) announced that Chief Medical Officer Dr. Alka Chaubey presented key findings at The Festival of Genomics & Biodata. The presentation emphasized Optical Genome Mapping (OGM) as a potential first-line test for diagnosing genetic diseases and cancers. Dr. Chaubey highlighted OGM's ability to detect all classes of structural variants (SVs), outperforming traditional methods like NGS. CEO Erik Holmlin expressed confidence in Saphyr’s role in revolutionizing cytogenomics, as evidenced by positive customer feedback.

Bionano Genomics announced the release of version 1.2 of its Compute On Demand (COD) solution, significantly lowering costs and analysis time for structural variant analysis in human genomes. With the integration of Microsoft Azure as a High-Performance Computing provider, compute costs are reduced by over 50% and processing time by 30%, providing results in just 9 hours. This update enhances throughput, allowing up to 96 samples per week, benefiting clinicians and researchers looking for faster insights into genetic diseases.

Bionano Genomics (BNGO) has successfully closed an underwritten public offering of 38,333,352 shares at $6.00 each, generating approximately $230 million in gross proceeds. This includes 5,000,002 shares from the underwriters' full exercise of their purchase option. The offering utilized a previously filed shelf registration statement that became effective on January 19, 2021. Oppenheimer & Co. Inc. acted as the sole book-running manager, with BTIG, LLC and others as co-managers. These funds will support the company's genome analysis tools for genetic research and diagnostics.

Bionano Genomics announced a public offering of 33,333,350 shares at $6.00 per share, aiming to raise approximately $200 million before expenses. The offering includes a 30-day option for underwriters to purchase up to 5,000,002 additional shares. The offering is set to close on January 22, 2021, subject to customary conditions. Oppenheimer & Co. is the sole book-running manager, with BTIG and others acting as co-managers. The shares are offered under a shelf registration statement effective January 19, 2021. Investors are encouraged to review the final prospectus for more details.

Bionano Genomics (Nasdaq: BNGO) announced plans for an underwritten public offering of its common stock, subject to market conditions. The offering aims to raise capital, though no details regarding size or terms are confirmed. Bionano intends to grant underwriters a 30-day option for an additional 15% of shares for over-allotments. Oppenheimer & Co. Inc. leads the offering, with BTIG, Ladenburg Thalmann, and Maxim Group as co-managers. The offering is registered under a previously filed shelf registration statement, effective since January 19, 2021.

Bionano Genomics announced the publication of a study comparing its Saphyr system with traditional cytogenomics methods for analyzing Myelodysplastic Syndromes (MDS). The study showed that optical genome mapping (OGM) detected all actionable variants and additional relevant aberrations missed by standard methodologies, enhancing clinical decision-making. Saphyr reduces the diagnostic process from weeks to just 4 days, potentially accelerating patient treatment. With OGM's high-throughput capabilities, it may streamline chromosomal analysis for MDS and other cancers.